Molly Olm-Shipman on Preserving Autonomy in Patients with Breast Cancer

Video

Molly Olm-Shipman talks about how a nurse can help ensure that the autonomy of patients with breast cancer is preserved.

Molly Olm-Shipman, BSN, RN, at Memorial Sloan Kettering Cancer Center, highlights the importance of preserving autonomy in patients with breast cancer by offering options.

She encourages two-way conversations when it comes to treatment discussions with patients and side effect management after radiation therapy. While the patient’s decision may not necessarily make medical sense, it is important for nurses and all other healthcare providers to really listen to a patient’s values and desires.

Related Videos
Related Content
Rx Road Map: Abemaciclib (Verzenio)

Rx Road Map: Abemaciclib (Verzenio)

April 18th 2024
Article

Sarah Montini, BSN, RN, OCN, provides an in-depth look at abemaciclib for the treatment of patients with breast cancer in a downloadable reference sheet.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Preoperative Systemic Therapy May Improve Survival vs Mastectomy in HER2+ Breast Cancer

Preoperative Systemic Therapy May Improve Survival vs Mastectomy in HER2+ Breast Cancer

April 16th 2024
Article

Breast-conserving therapy following preoperative systemic therapy resulted in superior overall survival compared with mastectomy in patients with HER2-positive breast cancer.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

FDA Accepts BLA for Dato-Dxd in HR+/HER2– Metastatic Breast Cancer

FDA Accepts BLA for Dato-Dxd in HR+/HER2– Metastatic Breast Cancer

April 3rd 2024
Article

The biologics license application for datopotamab deruxtecan has been accepted by the FDA for pretreated HR-positive, HER2-negative metastatic breast cancer.

Ribociclib Plus Endocrine Therapy Extends Invasive Disease-Free Survival in Early-Stage Breast Cancer

Ribociclib Plus Endocrine Therapy Extends Invasive Disease-Free Survival in Early-Stage Breast Cancer

March 30th 2024
Article

Patients with early-stage breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor provided a greater invasive disease-free survival benefit compared with nonsteroidal aromatase inhibitor therapy alone.

© 2024 MJH Life Sciences

All rights reserved.